- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment | ||
| Di | Consumer health giant Kenvue kicks off CEO transition as sales slip | ||
| Di | As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting | ||
| Di | As Perrigo's streamlining takes shape, self-care specialist offloads OTC dermatology unit for up to €327M | ||
| Mo | China biotechs 'reshaping' US biopharma as outlicensing deals rise 11%: Jefferies report | ||
| Mo | Humana kicks off virtual brain health challenge ahead of National Senior Games | ||
| Mo | Sun Pharma's alopecia med Leqselvi hits US market after Incyte patent settlement | ||
| Mo | BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis | ||
| Mo | Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant | ||
| Mo | Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues | ||
| Mo | Varda reels in $187M series C to propel drug manufacturing in space | ||
| Mo | Bayer's Kerendia wins FDA label expansion to treat certain patients with heart failure | ||
| Mo | On heels of Gilead deal, Leo pays Boehringer Ingelheim €90 million up front for Spevigo | ||
| Fr | The advantages of lab-based RWD for precise HCP identification | ||
| Fr | Zantac drugmakers notch key win in Delaware as court tosses expert testimony for plaintiffs | ||
| Fr | Karyopharm lays off more workers as hunt for strategic alternatives turns up short | ||
| Fr | Bayer scores first approval for hormone-free menopause drug Lynkuet in UK | ||
| Fr | Jazz hits a sour note in back-to-back rebukes from UK marketing watchdog | ||
| Fr | Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade | ||
| Fr | 'Weak evidence' and an 'unpleasant' odor: FDA sheds light on drug refusal process | ||
| Do | State AGs unveil opioid settlements totaling $720M with 8 drugmakers | ||
| Do | Astellas reports 22% sales bump for Izervay, expects trend to continue this year | ||
| Do | Insulet, Medtronic laud debut of first Barbie with Type 1 diabetes | ||
| Do | Pfizer, Astellas boost case for Xtandi in early-stage prostate cancer with combo survival win | ||
| Do | Pressuring Merck's Gardasil, China's home-made 9-valent HPV vaccine priced at 60% discount |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .